Navigation Links
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Date:7/24/2009

KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia.

Negative symptoms of schizophrenia include apathy, lack of emotion and poor social functioning, among others. In the study, these symptoms were assessed using the validated 16-item Negative Symptom Assessment scale (NSA-16).

"These symptoms are among the most difficult to treat in the schizophrenia spectrum," said Armin Szegedi, M.D., Ph.D., vice president, global clinical research, central nervous system, Schering-Plough Research Institute. "Few studies with the antipsychotics currently available on the market have been designed specifically to evaluate long-term effects on predominant, persistent negative symptoms. The results from this large clinical study program will provide new insights into potential treatment of these symptoms."

In the study, SAPHRIS was significantly more effective than olanzapine in the reduction of negative symptoms as measured by change from baseline to Day 365 in the NSA-16 total score, the primary endpoint of the study. By using a mixed model for repeated measures (MMRM), least square mean changes in the NSA-16 total score were -15.8 for SAPHRIS vs. -11.0 for olanzapine (P=0.015). Full results of the trial, including efficacy, safety and tolerability data, will be submitted for presentation at a medical meeting at a later date.

These results follow those of a previously reported clinical trial in this patient population using the same study design and protocol in which both asenapine and olanzapi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
2. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
5. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
6. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
9. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
10. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
11. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015 Pharmaco-Kinesis Corporation ... (NOCAB) recently convened at Shutters on the Beach in ... the development status of the Company,s innovative Metronomic Biofeedback ... to locally deliver chemotherapy over time to a target ... delivery capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... , 26. mája 2015 Kevin ... svojej rodiny prezidentom Barackovi Obamovi a Billovi Clintonovi ... so stratou Dr. Rongxiang Xu , otca ... Dr. Xu bol pionier, inovátor, ... jeho odhodlanie v oblasti vedy a príkladné vedenie ...
(Date:5/26/2015)... MENLO PARK, Calif. , May 26, 2015 /PRNewswire/ ... focused on the emerging field of regenerative medicine, today ... issued in June 2014 were exercised prior to their ... to the Company of $11.7 million. "We ... Pedro Lichtinger , President and CEO of Asterias. "This ...
(Date:5/26/2015)... , May 26, 2015 /PRNewswire/ - Fluorinov Pharma ... of Luke M. Beshar to its Board ... financial and pharmaceutical industry expertise as Fluorinov accelerates its ... the Fluorinov team, it is a pleasure to welcome ... a significant impact on the strategy, financial strength and ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, O legende 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... University today announced the public launch of the Tufts ...   The Institute is a university-wide, global ... diverse portfolio of drug discovery and development partnerships. ... by Tufts University School of Medicine and Tufts University,s ...
... Calif., Feb. 11, 2011 Abaxis, Inc. (Nasdaq: ... blood analysis instruments for the medical, research and veterinary ... Scandinavian Micro Biodevices APS, ("SMB"), a privately-held developer and ... SMB, based in Copenhagen, Denmark, has been ...
... 11, 2011 ImmunGene, Inc., a privately held drug ... that a profile of the company and its interferon ... in the February 7 issue of BioCentury , ... pharma and biotech industries. ( www.biocentury.com ) ...
Cached Biology Technology:Tufts Launches Institute for Biopharmaceutical Partnerships 2Tufts Launches Institute for Biopharmaceutical Partnerships 3Tufts Launches Institute for Biopharmaceutical Partnerships 4Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS 2Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS 3Abaxis Makes $2.8 Million Equity Investment in Scandinavian Micro Biodevices APS 4ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine 2
(Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... in German . , EUMINAfab offers ... nanotechnologies for users from science and industry. Today, this ... Ten leading institutions from research and industry in eight ... high-tech installations along with the corresponding scientific and technological ...
... about how fat causes hypertension have been identified by researchers ... obese people and maybe some thin ones too ... best for them. Medical College of Georgia researchers ... mice at risk for hypertension by interfering with an endogenous ...
... of the world,s top cancer specialists will be in ... International Cancer Symposium organised by Queen,s University. The ... and Cancer Research (CCRCB) on Wednesday and Thursday, will ... and Europe, including those from Harvard Medical School in ...
Cached Biology News:Scientific pathways into the nanoworld 2Scientific pathways into the nanoworld 3New information about how fat increases blood pressure could help identify those at risk 2New information about how fat increases blood pressure could help identify those at risk 3International event brings world's top cancer doctors to Queen's 2International event brings world's top cancer doctors to Queen's 3
... of several isoprostanes produced from arachidonic acid during ... in the rat. 8-iso PGE2 inhibits U-46619 or ... and 5 µM, respectively. When infused into the ... of 4 mg/kg/min, 8-iso PGE2 decreases the GFR ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: